Human Insulin Market Synopsis

Human Insulin Market Size is Valued at USD 19.19 Billion in 2023, and is Projected to Reach USD 25.25 Billion by 2032, Growing at a CAGR of 3.10% From 2024-2032.

Human insulin market refers to the manufacturing, supply, and marketing of insulin products that are used in regulating blood glucose in diabetics. This market also covers both the regular human insulin like short-acting and intermediate-acting insulin and the modern human insulin like rapid-acting insulin, long-acting insulin and pre-mixed insulin. The market can be divided by the type of product, brand, delivery systems, uses, customer base, the channel of distribution, and region. There are now a variety of delivery systems available in this market such as insulin pens, pumps, syringes, vials, and cartridges whereby different players address the needs of different patients and healthcare facilities around the world.

• The market for human insulin is mainly due to the rising rate of diabetes around the world and the need for proper regulation of blood glucose levels. The global demand for human insulin is driven by a staggering increase in Type 1 and Type 2 diabetes across the globe and increasing awareness concerning diabetes management. Current development in biotechnology has seen the creation of better insulin delivery systems like insulin pens and pumps that help increase patient adherence to the required regimen and improve their overall well-being. Also, policies implemented by governments and various reimbursements policies in different countries also boost market growth by increasing the accessibility of insulin products among the population.
• Also, there is ongoing innovation by the pharmaceutical companies in coming up with the modern human insulin such as rapid and long-acting insulin. These newer formulations provide improved glycemic control and fewer side effects than traditional insulin and are preferable to the patients and the health care practitioners. In addition, more money has been invested in research and development of biosimilar insulin products, which has ensured that these treatment options are affordable and can reach out to more people in the emerging markets. Moreover, the advancement in the internet-based pharmacies and better health care facilities have also led to the growth of the market by increasing the availability of insulin products across the world.

Human Insulin Market Trend Analysis

Rising Demand and Innovations Fuel Human Insulin Market Growth

• The Human Insulin market is growing rapidly due to increasing diabetes type population base across the world and new innovations in insulin delivery systems. The rising incidence rate of Diabetes and growing consciousness among the patients of diabetes is the factor on which human insulin demand is increasing. Advancements in technologies like insulin pumps, insulin pens and smart insulin patch are easy to use, quick and accurate hence preferred by many patients and healthcare providers. Moreover, sustained R&D processes to enhance the insulin formulation and its delivery systems are projected to continue to boost market growth.
• Moreover, there is a market trend towards the new generation of insulin analogues which has a better efficacy/side effect profile than human insulin. These are the rapid-acting and long-acting insulin analogs have been slowly introduced to the market due to the better glycemic control and flexibility in the times of administration. Market growth is also driven by governmental actions and legislation aimed at the diabetes care, and the rising medical expenditure in the developing countries. North America and Europe are considered as the leading markets, but Asia-Pacific and Latin America are expected to have higher growth potential due to the advancing healthcare systems and patients’ awareness.

Strategic Developments in the Human Insulin Market

• The market for human insulin is full of great potential due to the growing incidence of diabetes globally. Owing to the increasing prevalence of Type 1 and Type 2 diabetes, the need for insulin-based treatments remains high. Innovations in the field of biotechnology and pharmacology have produced the improved insulin analogues that are used today, which are more effective in controlling glycemia and less dangerous than regular insulin. Advancements like insulin pumps, pens and other methods of delivery make it easier for patients to follow prescribed regimes, thus also driving the market. Furthermore, a growing number of patients with diabetes, thanks to early diagnosis and greater awareness of the disease, are demanding insulin.
• Asia-Pacific and Latin America regions remain the most attractive for growth as the number of diabetic people is rising and healthcare systems are being developed. To a greater extent, the growth of the market is driven by governments’ actions and healthcare reforms to improve the management and availability of diabetes care and treatments. In addition, joint ventures and alliances, along with acquisitions and joint ventures, have promoted the advancement and expansion of key market players. Spending in research and development to develop affordable biosimilar insulin products offer cheaper treatment solutions to boost market accessibility. All in all, the human insulin market is expected to grow at a healthy rate in the foreseeable future due to the factors such as technological innovation, increasing diabetic patients’ population, and increased accessibility to healthcare facilities all over the world.

Human Insulin Market Segment Analysis:

Human Insulin Market Segmented on the basis of Product type, Delivery Mode, Application and end-users.

By Product Type, Traditional Human Insulin segment is expected to dominate the market during the forecast period

• By product type the human insulin market can be bifurcated as traditional human insulin and the modern human insulin. Regular human insulin includes the short acting insulin and the intermediate acting insulin, which are types of insulin that are most natural to the body but requires one to adhere strictly to the meal times and frequent blood tests. However, modern human insulin also referred to as insulin analogs have rapid, long and premixed insulin types.
• These analogs are designed to give better control over blood sugar and precise, more predictable control of blood sugar levels, thereby enabling greater freedom of choice for the patient and better glycemic control. Among the factors that are driving this market is the preference for more advanced insulin analogues that have low likelihood of hypoglycemia and which allow for less frequent injections.

By Application, Type 1 Diabetes segment held the largest share in 2024

• In human insulin market segmentation is done based on applications and these are principally, Type I and Type II diabetes. Another type of diabetes, namely, type 1 diabetes, is an autoimmune disease that develops when the body produces minimal or no insulin at all, and thus, demands insulin treatment throughout the patient’s entire life starting from the time of diagnosis. Type 1 diabetics require both basal insulin, which mimics the slow release of insulin throughout the day and night, and bolus insulin, which is used for mealtime when glucose levels are anticipated to spike.
• On the other hand, Type 2 diabetes where the body tends to become resistant to insulin and or the pancreas gradually produces little insulin has early treatment with pills and alteration of diet. Nevertheless, progression of the disease and poor compliance often result in the need for supplemental insulin therapy among patients with Type 2 diabetes. Due to the rise in the population living with both type one and type two diabetes with type two being associated with lifestyle choices and ageing populations the market for various insulin types catering for the different population is expanding.

Human Insulin Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• The North American human insulin market can be considered as one of the biggest and most developed markets in the world. It is due to the high incidence of diabetes, growing awareness of diabetes management, and the availability of the latest healthcare technologies. The American continent is dominant and has a large number of diabetics and actively developing new insulin therapies. Canada is another significant market, which has been experiencing increased demand for insulin products and has a favourable healthcare system.
• In North America, technological improvements in the insulin delivery systems, including insulin pens, pumps, and others, have also boosted the market growth in recent years. Further, the market has significant players like Eli Lilly, Novo Nordisk, and Sanofi in the market that has led to high competition, which in turn has been instrumental in the introduction of new insulin products into the market. The North American market is also predicted to grow because of the growing incidence of diabetes, the elevated healthcare costs, and continued innovation in the management of diabetes.

Active Key Players in the Human Insulin Market

• Novo Nordisk A/S (Denmark)
• Eli Lilly and Company (U.S.)
• Sanofi (France)
• BIOTON S.A. (Poland)
• Gan & Lee Pharmaceuticals (China)
• Biocon (India)
• Tonghua Dongbao Pharmaceutical (China)
• Julphar (UAE)
• Wockhardt (India)
• Others

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Human Insulin Market by Product Type
 4.1 Human Insulin Market Snapshot and Growth Engine
 4.2 Human Insulin Market Overview
 4.3 Traditional Human Insulin
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Traditional Human Insulin: Geographic Segmentation Analysis
 4.4 Modern Human Insulin
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Modern Human Insulin: Geographic Segmentation Analysis

Chapter 5: Human Insulin Market by Delivery Method
 5.1 Human Insulin Market Snapshot and Growth Engine
 5.2 Human Insulin Market Overview
 5.3 Insulin Pens
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Insulin Pens: Geographic Segmentation Analysis
 5.4 Insulin Pumps
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Insulin Pumps: Geographic Segmentation Analysis
 5.5 Insulin Syringes
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Insulin Syringes: Geographic Segmentation Analysis
 5.6 Vials
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Vials: Geographic Segmentation Analysis
 5.7 Cartridges
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Cartridges: Geographic Segmentation Analysis

Chapter 6: Human Insulin Market by Application
 6.1 Human Insulin Market Snapshot and Growth Engine
 6.2 Human Insulin Market Overview
 6.3 Type 1 Diabetes
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Type 1 Diabetes: Geographic Segmentation Analysis
 6.4 Type 2 Diabetes
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Type 2 Diabetes: Geographic Segmentation Analysis

Chapter 7: Human Insulin Market by End-User
 7.1 Human Insulin Market Snapshot and Growth Engine
 7.2 Human Insulin Market Overview
 7.3 Hospitals
  7.3.1 Introduction and Market Overview
  7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.3.3 Key Market Trends, Growth Factors and Opportunities
  7.3.4 Hospitals: Geographic Segmentation Analysis
 7.4 Clinics
  7.4.1 Introduction and Market Overview
  7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.4.3 Key Market Trends, Growth Factors and Opportunities
  7.4.4 Clinics: Geographic Segmentation Analysis
 7.5 Home Care
  7.5.1 Introduction and Market Overview
  7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.5.3 Key Market Trends, Growth Factors and Opportunities
  7.5.4 Home Care: Geographic Segmentation Analysis
 7.6 Specialty Diabetes Centers
  7.6.1 Introduction and Market Overview
  7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.6.3 Key Market Trends, Growth Factors and Opportunities
  7.6.4 Specialty Diabetes Centers: Geographic Segmentation Analysis
 7.7 Retail Pharmacies
  7.7.1 Introduction and Market Overview
  7.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  7.7.3 Key Market Trends, Growth Factors and Opportunities
  7.7.4 Retail Pharmacies: Geographic Segmentation Analysis

Chapter 8: Company Profiles and Competitive Analysis
 8.1 Competitive Landscape
  8.1.1 Competitive Benchmarking
  8.1.2 Human Insulin Market Share by Manufacturer (2023)
  8.1.3 Industry BCG Matrix
  8.1.4 Heat Map Analysis
  8.1.5 Mergers and Acquisitions
  
 8.2 NOVO NORDISK AS (DENMARK)
  8.2.1 Company Overview
  8.2.2 Key Executives
  8.2.3 Company Snapshot
  8.2.4 Role of the Company in the Market
  8.2.5 Sustainability and Social Responsibility
  8.2.6 Operating Business Segments
  8.2.7 Product Portfolio
  8.2.8 Business Performance
  8.2.9 Key Strategic Moves and Recent Developments
  8.2.10 SWOT Analysis
 8.3 ELI LILLY AND COMPANY (US)
 8.4 SANOFI (FRANCE)
 8.5 BIOTON SA (POLAND)
 8.6 GAN & LEE PHARMACEUTICALS (CHINA)
 8.7 BIOCON (INDIA)
 8.8 TONGHUA DONGBAO PHARMACEUTICAL (CHINA)
 8.9 JULPHAR (UAE)
 8.10 WOCKHARDT (INDIA)
 8.11 OTHERS

Chapter 9: Global Human Insulin Market By Region
 9.1 Overview
 9.2. North America Human Insulin Market
  9.2.1 Key Market Trends, Growth Factors and Opportunities
  9.2.2 Top Key Companies
  9.2.3 Historic and Forecasted Market Size by Segments
  9.2.4 Historic and Forecasted Market Size By Product Type
   9.2.4.1 Traditional Human Insulin
   9.2.4.2 Modern Human Insulin
  9.2.5 Historic and Forecasted Market Size By Delivery Method
   9.2.5.1 Insulin Pens
   9.2.5.2 Insulin Pumps
   9.2.5.3 Insulin Syringes
   9.2.5.4 Vials
   9.2.5.5 Cartridges
  9.2.6 Historic and Forecasted Market Size By Application
   9.2.6.1 Type 1 Diabetes
   9.2.6.2 Type 2 Diabetes
  9.2.7 Historic and Forecasted Market Size By End-User
   9.2.7.1 Hospitals
   9.2.7.2 Clinics
   9.2.7.3 Home Care
   9.2.7.4 Specialty Diabetes Centers
   9.2.7.5 Retail Pharmacies
  9.2.8 Historic and Forecast Market Size by Country
   9.2.8.1 US
   9.2.8.2 Canada
   9.2.8.3 Mexico
 9.3. Eastern Europe Human Insulin Market
  9.3.1 Key Market Trends, Growth Factors and Opportunities
  9.3.2 Top Key Companies
  9.3.3 Historic and Forecasted Market Size by Segments
  9.3.4 Historic and Forecasted Market Size By Product Type
   9.3.4.1 Traditional Human Insulin
   9.3.4.2 Modern Human Insulin
  9.3.5 Historic and Forecasted Market Size By Delivery Method
   9.3.5.1 Insulin Pens
   9.3.5.2 Insulin Pumps
   9.3.5.3 Insulin Syringes
   9.3.5.4 Vials
   9.3.5.5 Cartridges
  9.3.6 Historic and Forecasted Market Size By Application
   9.3.6.1 Type 1 Diabetes
   9.3.6.2 Type 2 Diabetes
  9.3.7 Historic and Forecasted Market Size By End-User
   9.3.7.1 Hospitals
   9.3.7.2 Clinics
   9.3.7.3 Home Care
   9.3.7.4 Specialty Diabetes Centers
   9.3.7.5 Retail Pharmacies
  9.3.8 Historic and Forecast Market Size by Country
   9.3.8.1 Bulgaria
   9.3.8.2 The Czech Republic
   9.3.8.3 Hungary
   9.3.8.4 Poland
   9.3.8.5 Romania
   9.3.8.6 Rest of Eastern Europe
 9.4. Western Europe Human Insulin Market
  9.4.1 Key Market Trends, Growth Factors and Opportunities
  9.4.2 Top Key Companies
  9.4.3 Historic and Forecasted Market Size by Segments
  9.4.4 Historic and Forecasted Market Size By Product Type
   9.4.4.1 Traditional Human Insulin
   9.4.4.2 Modern Human Insulin
  9.4.5 Historic and Forecasted Market Size By Delivery Method
   9.4.5.1 Insulin Pens
   9.4.5.2 Insulin Pumps
   9.4.5.3 Insulin Syringes
   9.4.5.4 Vials
   9.4.5.5 Cartridges
  9.4.6 Historic and Forecasted Market Size By Application
   9.4.6.1 Type 1 Diabetes
   9.4.6.2 Type 2 Diabetes
  9.4.7 Historic and Forecasted Market Size By End-User
   9.4.7.1 Hospitals
   9.4.7.2 Clinics
   9.4.7.3 Home Care
   9.4.7.4 Specialty Diabetes Centers
   9.4.7.5 Retail Pharmacies
  9.4.8 Historic and Forecast Market Size by Country
   9.4.8.1 Germany
   9.4.8.2 UK
   9.4.8.3 France
   9.4.8.4 Netherlands
   9.4.8.5 Italy
   9.4.8.6 Russia
   9.4.8.7 Spain
   9.4.8.8 Rest of Western Europe
 9.5. Asia Pacific Human Insulin Market
  9.5.1 Key Market Trends, Growth Factors and Opportunities
  9.5.2 Top Key Companies
  9.5.3 Historic and Forecasted Market Size by Segments
  9.5.4 Historic and Forecasted Market Size By Product Type
   9.5.4.1 Traditional Human Insulin
   9.5.4.2 Modern Human Insulin
  9.5.5 Historic and Forecasted Market Size By Delivery Method
   9.5.5.1 Insulin Pens
   9.5.5.2 Insulin Pumps
   9.5.5.3 Insulin Syringes
   9.5.5.4 Vials
   9.5.5.5 Cartridges
  9.5.6 Historic and Forecasted Market Size By Application
   9.5.6.1 Type 1 Diabetes
   9.5.6.2 Type 2 Diabetes
  9.5.7 Historic and Forecasted Market Size By End-User
   9.5.7.1 Hospitals
   9.5.7.2 Clinics
   9.5.7.3 Home Care
   9.5.7.4 Specialty Diabetes Centers
   9.5.7.5 Retail Pharmacies
  9.5.8 Historic and Forecast Market Size by Country
   9.5.8.1 China
   9.5.8.2 India
   9.5.8.3 Japan
   9.5.8.4 South Korea
   9.5.8.5 Malaysia
   9.5.8.6 Thailand
   9.5.8.7 Vietnam
   9.5.8.8 The Philippines
   9.5.8.9 Australia
   9.5.8.10 New Zealand
   9.5.8.11 Rest of APAC
 9.6. Middle East & Africa Human Insulin Market
  9.6.1 Key Market Trends, Growth Factors and Opportunities
  9.6.2 Top Key Companies
  9.6.3 Historic and Forecasted Market Size by Segments
  9.6.4 Historic and Forecasted Market Size By Product Type
   9.6.4.1 Traditional Human Insulin
   9.6.4.2 Modern Human Insulin
  9.6.5 Historic and Forecasted Market Size By Delivery Method
   9.6.5.1 Insulin Pens
   9.6.5.2 Insulin Pumps
   9.6.5.3 Insulin Syringes
   9.6.5.4 Vials
   9.6.5.5 Cartridges
  9.6.6 Historic and Forecasted Market Size By Application
   9.6.6.1 Type 1 Diabetes
   9.6.6.2 Type 2 Diabetes
  9.6.7 Historic and Forecasted Market Size By End-User
   9.6.7.1 Hospitals
   9.6.7.2 Clinics
   9.6.7.3 Home Care
   9.6.7.4 Specialty Diabetes Centers
   9.6.7.5 Retail Pharmacies
  9.6.8 Historic and Forecast Market Size by Country
   9.6.8.1 Turkey
   9.6.8.2 Bahrain
   9.6.8.3 Kuwait
   9.6.8.4 Saudi Arabia
   9.6.8.5 Qatar
   9.6.8.6 UAE
   9.6.8.7 Israel
   9.6.8.8 South Africa
 9.7. South America Human Insulin Market
  9.7.1 Key Market Trends, Growth Factors and Opportunities
  9.7.2 Top Key Companies
  9.7.3 Historic and Forecasted Market Size by Segments
  9.7.4 Historic and Forecasted Market Size By Product Type
   9.7.4.1 Traditional Human Insulin
   9.7.4.2 Modern Human Insulin
  9.7.5 Historic and Forecasted Market Size By Delivery Method
   9.7.5.1 Insulin Pens
   9.7.5.2 Insulin Pumps
   9.7.5.3 Insulin Syringes
   9.7.5.4 Vials
   9.7.5.5 Cartridges
  9.7.6 Historic and Forecasted Market Size By Application
   9.7.6.1 Type 1 Diabetes
   9.7.6.2 Type 2 Diabetes
  9.7.7 Historic and Forecasted Market Size By End-User
   9.7.7.1 Hospitals
   9.7.7.2 Clinics
   9.7.7.3 Home Care
   9.7.7.4 Specialty Diabetes Centers
   9.7.7.5 Retail Pharmacies
  9.7.8 Historic and Forecast Market Size by Country
   9.7.8.1 Brazil
   9.7.8.2 Argentina
   9.7.8.3 Rest of SA

Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies

Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research